China News Agency, Urumqi, December 17 (Reporter Sun Tingwen) The state organizes centralized drug procurement (referred to as the National Centralized Procurement) to drastically reduce drug prices, reduce the medical burden of Xinjiang people, and improve the quality of drugs used by the people.
The reporter learned from the press conference held in Xinjiang on the 17th that up to now, the national centralized procurement has been fully implemented in Xinjiang.
Wang Zhihua, deputy secretary and deputy director of the Xinjiang Medical Security Bureau, stated that the first batch of national centralized procurement was launched in Xinjiang on December 20, 2019; the second batch was launched at the end of April 2020; the third batch was launched on November 20 Implementation in Xinjiang.
Wang Zhihua said that the national centralized procurement has strongly promoted the return of drug prices to a reasonable level.
For example, the national coronary stent price dropped from an average price of about 13,000 yuan (RMB, the same below) to about 700 yuan.
According to statistics, the number of coronary stents used in Xinjiang in 2019 was close to 30,000.
This time, the state's centralized recruitment and procurement from Xinjiang declared a purchase volume of 32,000.
According to the national average price, Xinjiang’s insured patients and medical insurance fund can save about 320 million yuan in medical expenses each year. Xinjiang plans to implement the results of the election in January 2021, so that people in Xinjiang can enjoy the reform of centralized procurement. dividend.
He also said that the prices of selected varieties in national centralized procurement have dropped by more than 50% compared with the original prices. After the overall implementation of the three batches of centralized procurement, Xinjiang can directly reduce medical expenses by about 600 million yuan each year. Some chronic diseases and cancers The price reduction experience for patients is particularly obvious.
Centralized procurement with volume will give 50%-80% of the market procurement volume to drugs that have passed the quality and efficacy consistency evaluation of generic drugs, achieving "quality improvement and price reduction".
The price reduction effect and the substitution effect are superimposed, and the burden reduction effect of the people is obvious, which has significantly improved the quality of drugs used by the people in Xinjiang.
Data show that as of late November, the first batch of 25 selected drugs in Xinjiang had all completed the procurement task, and the actual reduction in expenditures for patients and medical insurance funds was about 485 million yuan compared with last year.
The second batch of 32 selected drugs has completed 97% of the total tasks, and the actual reduction of expenditures for patients and medical insurance funds is about 160 million yuan.
(Finish)